stockportfolio.pro
Bristol-Myers Squibb Company P/E Ratio 2007–2025
Bristol-Myers Squibb Company (BMY) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +1.3%/yr over 18 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 15.25 | — |
| FY 2024 | — | — |
| FY 2023 | 11.79 | -43.6% |
| FY 2022 | 20.89 | +25.8% |
| FY 2021 | 16.60 | — |
| FY 2020 | — | — |
| FY 2019 | 24.95 | +91.3% |
| FY 2018 | 13.04 | -82.3% |
| FY 2017 | 73.88 | +367.9% |
| FY 2016 | 15.79 | -69.5% |
| FY 2015 | 51.72 | +54.0% |
| FY 2014 | 33.59 | +46.6% |
| FY 2013 | 22.91 | +27.2% |
| FY 2012 | 18.02 | +79.1% |
| FY 2011 | 10.06 | +15.6% |
| FY 2010 | 8.70 | +228.4% |
| FY 2009 | 2.65 | -43.6% |
| FY 2008 | 4.70 | -61.4% |
| FY 2007 | 12.18 | — |
Source: Bristol-Myers Squibb Company SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Bristol-Myers Squibb Company
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBristol-Myers Squibb Company — frequently asked questions
What is Bristol-Myers Squibb Company's price-to-earnings ratio?
Bristol-Myers Squibb Company (BMY) reported price-to-earnings ratio of 15.25 for fiscal year 2025, per its SEC filings.
How has Bristol-Myers Squibb Company's price-to-earnings ratio changed over time?
Between fiscal 2007 and 2025, BMY's price-to-earnings ratio grew at roughly 1.3% per year (compound annual rate), from 12.18 to 15.25.
Where does this data come from?
Figures are computed from Bristol-Myers Squibb Company's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.